Exposure from diet regularly exceeds the ADI in children
EFSA set a group ADI of 30mg per kilogram of bodyweight per day for all glutamate additives combined. However, exposure estimates for infants, toddlers and children at high consumption levels exceeded not only the ADI but also doses linked to adverse effects in human studies. Adults can also breach the ADI through heavy processed-food use.
EFSA derived a group ADI of 30mg/kg bodyweight per day for glutamic acid and glutamates (E620-E625) expressed as glutamic acid, and found that dietary exposure exceeded this ADI across all age groups at mean and high consumption levels.
2017Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources (ANS), re-evaluation of glutamic acid (E620) to magnesium glutamate (E625), EFSA Journal
Modelled exposure exceeded doses associated with MSG symptom complex (above roughly 43mg/kg/day), headaches (above roughly 86mg/kg/day), and blood-pressure rises (above roughly 150mg/kg/day) in some high-consuming children.
2017Regulatory reviewEFSA Journal, ANS Panel re-evaluation of glutamates (E620-E625)
MSG symptom complex: real in some people, disputed as a population risk
A subset of people report headaches, flushing, chest tightness and sweating after consuming large amounts of glutamate, a pattern historically called 'Chinese restaurant syndrome'. Controlled blinded studies have produced mixed results: symptoms are difficult to reproduce consistently in double-blind conditions, but high-dose challenges in sensitive individuals do show effects in some trials. The mechanism is not fully established.
Double-blind crossover trials in self-reported MSG-sensitive individuals have produced inconsistent results, with some studies finding no significant symptom difference versus placebo at moderate doses and others finding effects at high doses.
2000RCTGeha RS et al., Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate, Journal of Allergy and Clinical Immunology
EFSA concluded that available data were insufficient to establish a dose-response relationship for the MSG symptom complex and recommended further research.
2017Regulatory reviewEFSA Journal, ANS Panel re-evaluation of glutamates (E620-E625)
Animal and developmental toxicity: no adverse histopathological findings at high doses
In animal studies, glutamates showed low acute toxicity. Increased kidney and spleen weights were observed at very high doses but were not accompanied by tissue damage and were not classified as adverse by the EFSA panel. No genotoxicity was found. Neurodevelopmental effects observed in some older animal studies were not reproduced under more rigorous conditions.
The NOAEL used to set the ADI came from a neurodevelopmental toxicity study in rats; no adverse histopathological findings accompanied organ-weight changes seen at higher doses, and genotoxicity testing raised no concerns.
2017AnimalEFSA Journal, ANS Panel re-evaluation of glutamates (E620-E625)
Regulatory recommendation to lower maximum permitted levels
Because modelled exposure exceeded the ADI across multiple age groups, EFSA recommended in 2017 that the European Commission revise the maximum permitted levels for glutamate additives in the principal food categories. As of the most recent regulatory review, those revisions had not been fully implemented.
The EFSA panel recommended that the European Commission reconsider the maximum permitted levels for glutamate food additives (E620-E625) in Annex II of Regulation 1333/2008 to bring estimated exposure within the ADI.
2017RegulatoryEFSA Journal, ANS Panel re-evaluation of glutamates (E620-E625)